. 2022 Oct 27;128(24):4251–4284. doi: 10.1002/cncr.34479

TABLE 1.

Age‐standardized, delay‐adjusted incidence rates ^a and fixed‐interval trends (2014–2018) ^b for the most common cancers, ^c all ages, by sex, age group, and racial/ethnic group ^d for areas in the United States with high‐quality incidence data ^e

Sex/cancer site or type		All racial/ethnic groups			Non‐Hispanic White			Non‐Hispanic Black			Non‐Hispanic API			Non‐Hispanic AI/AN, PRCDA			Hispanic
Sex/cancer site or type	Rank	Rate (95% CI)	AAPC (95% CI)	p	Rate (95% CI)	AAPC (95% CI)	p	Rate (95% CI)	AAPC (95% CI)	p	Rate (95% CI)	AAPC (95% CI)	p	Rate (95% CI)	AAPC (95% CI)	p	Rate (95% CI)	AAPC (95% CI)	p
All sites ^f
Both sexes		457.5 (457.2–457.8)	−0.2 (−0.5, 0.1)	.19	477.9 (477.5–478.3)	0.0 (−0.4, 0.3)	.91	467.8 (466.8–468.8)	−0.7 (−1.1, −0.4) ^g	< .001	305.5 (304.3–306.6)	−0.3 (−0.3, −0.2) ^g	< .001	488.3 (482.9–493.8)	0.6 (0.4–0.8) ^g	< .001	358.7 (357.9–359.6)	−0.1 (−0.4, 0.2)	.58
Males		497.4 (497.0–497.9)	−0.4 (−1.2, 0.3)	.22	514.2 (513.6–514.7)	−0.2 (−0.9, 0.5)	.55	544.0 (542.4–545.7)	−1.2 (−1.8, −0.5) ^g	.004	306.3 (304.5–308.1)	−1.2 (−1.4, −1.1) ^g	< .001	515.0 (506.5–523.6)	0.0 (−0.3, 0.3)	.86	384.0 (382.7–385.4)	−0.9 (−1.3, −0.5) ^g	< .001
Females		430.9 (430.4–431.3)	0.2 (0.1–0.3) ^g	< .001	454.0 (453.5–454.5)	0.3 (0.2–0.4) ^g	< .001	416.7 (415.4–417.9)	−0.3 (−0.7, 0.0)	.07	309.1 (307.5–310.6)	0.6 (0.6–0.7) ^g	< .001	473.3 (466.1–480.5)	1.1 (0.9–1.3) ^g	< .001	346.7 (345.6–347.8)	0.7 (0.5–0.9) ^g	< .001
Children, ages 0–14 years		17.8 (17.7–18.0)	0.0 (−1.6, 1.6)	1.00	18.7 (18.5–18.9)	1.0 (0.8–1.2) ^g	< .001	13.8 (13.5–14.2)	0.0 (−1.1, 1.1)	.97	17.2 (16.6–17.9)	2.3 (1.9–2.7) ^g	< .001	19.2 (17.4–21.2)	1.9 (0.6–3.2) ^g	.006	17.6 (17.3–17.9)	0.8 (0.6–1.1) ^g	< .001
AYAs, ages 15–39 years		77.9 (77.6–78.1)	0.9 (0.8–1.0) ^g	< .001	86.0 (85.7–86.4)	−0.2 (−1.5, 1.2)	.82	64.8 (64.2–65.4)	−0.7 (−2.2, 0.8)	.34	58.8 (58.0–59.6)	1.0 (0.3–1.6) ^g	.008	90.0 (86.4–93.7)	2.1 (1.6–2.6) ^g	< .001	65.8 (65.3–66.3)	2.4 (2.0–2.9) ^g	< .001
Males
Prostate	1	110.5 (110.3–110.7)	3.0 (−1.1, 7.2)	.13	104.9 (104.6–105.1)	3.7 (−0.8, 8.3)	.09	182.0 (181.1–183.0)	1.6 (−1.1, 4.5)	.22	58.8 (58.0–59.6)	4.4 (1.1–7.7) ^g	.01	89.1 (85.5–92.7)	0.7 (−2.8, 4.3)	.67	96.0 (95.4–96.7)	0.5 (−2.0, 3.2)	.65
Lung and bronchus	2	66.1 (66.0, 66.3)	−2.6 (−2.7, −2.4) ^g	< .001	70.0 (69.8–70.2)	−2.8 (−3.2, −2.3) ^g	< .001	78.3 (77.7–79.0)	−3.2 (−3.5, −2.9) ^g	< .001	43.3 (42.7–44.0)	−1.5 (−1.7, −1.3) ^g	< .001	73.0 (69.7–76.3)	−5.3 (−9.9, −0.6) ^g	.03	34.9 (34.5–35.3)	−2.7 (−2.9, −2.5) ^g	< .001
Colon and rectum	3	44.2 (44.0–44.3)	−1.2 (−1.6, −0.7) ^g	< .001	43.9 (43.7–44.0)	−1.2 (−1.5, −0.8) ^g	< .001	52.6 (52.0–53.1)	−2.7 (−2.9, −2.5) ^g	< .001	35.9 (35.3–36.5)	−2.0 (−2.3, −1.8) ^g	< .001	60.6 (57.7–63.6)	−0.2 (−0.9, 0.4)	.48	41.9 (41.4–42.3)	−2.0 (−2.3, −1.8) ^g	< .001
Urinary bladder	4	34.6 (34.4–34.7)	−2.1 (−2.9, −1.2) ^g	< .001	39.0 (38.9–39.2)	−2.0 (−2.8, −1.2) ^g	< .001	19.8 (19.5–20.1)	−1.7 (−2.9, −0.4) ^g	.01	15.2 (14.8–15.7)	−0.7 (−0.9, −0.4) ^g	< .001	27.0 (24.9–29.2)	1.8 (0.9–2.7) ^g	.001	18.8 (18.5–19.1)	−1.4 (−1.6, −1.2) ^g	< .001
Melanoma of the skin	5	29.3 (29.2–29.4)	0.5 (−1.6, 2.6)	.62	37.9 (37.7–38.0)	2.5 (2.2–2.7) ^g	< .001	1.1 (1.1–1.2)	−0.3 (−1.3, 0.6)	.50	1.6 (1.5–1.8)	−0.1 (−0.7, 0.4)	.62	13.6 (12.2–15.2)	−4.1 (−10.1, 2.3)	.20	5.1 (5.0–5.3)	0.3 (−0.2, 0.9)	.23
Non‐Hodgkin lymphoma	6	23.7 (23.6–23.8)	−0.9 (−1.7, −0.1) ^g	.03	25.0 (24.9–25.2)	−0.8 (−1.5, −0.1) ^g	.02	17.9 (17.6–18.2)	0.2 (−0.1, 0.4)	.15	16.5 (16.1–16.9)	0.4 (0.1–0.7) ^g	.03	20.1 (18.5–21.9)	0.0 (−1.0, 1.0)	.97	20.4 (20.1–20.7)	0.1 (−0.2, 0.4)	.54
Kidney and renal pelvis	7	23.6 (23.5–23.7)	0.7 (0.4–1.1) ^g	< .001	24.0 (23.9–24.2)	1.0 (0.4–1.6) ^g	.001	26.7 (26.3–27.1)	−1.4 (−3.3, 0.5)	.15	11.7 (11.3–12.0)	0.7 (−0.4, 1.7)	.19	41.7 (39.4–44.1)	2.6 (1.7–3.5) ^g	< .001	21.8 (21.5–22.1)	0.8 (−1.0, 2.7)	.37
Leukemia	8	19.5 (19.4–19.6)	−0.6 (−1.4, 0.1)	.10	20.9 (20.8–21.0)	−1.0 (−2.3, 0.3)	.11	14.8 (14.5–15.1)	0.9 (0.4–1.3) ^g	< .001	11.0 (10.7–11.3)	0.6 (−0.7, 1.9)	.33	17.7 (16.2–19.4)	1.4 (0.4–2.5) ^g	.01	14.4 (14.2–14.7)	0.7 (0.3–1.1) ^g	.002
Oral cavity and pharynx	9	18.4 (18.3–18.5)	0.2 (−1.2, 1.7)	.73	20.5 (20.3–20.6)	0.7 (−0.7, 2.1)	.34	14.0 (13.8–14.3)	−1.9 (−2.1, −1.6) ^g	< .001	12.2 (11.8–12.5)	0.9 (0.5–1.3) ^g	< .001	19.6 (18.1–21.3)	2.3 (1.2–3.4) ^g	< .001	11.2 (11.0–11.4)	−0.5 (−0.8, −0.1) ^g	.01
Pancreas	10	15.1 (15.0–15.2)	1.1 (1.0–1.2) ^g	< .001	15.3 (15.2–15.4)	1.3 (1.2–1.4) ^g	< .001	18.0 (17.7–18.3)	0.7 (0.4–0.9) ^g	< .001	10.5 (10.2–10.9)	0.6 (0.3–0.9) ^g	.001	16.7 (15.2–18.3)	2.6 (1.2–4.0) ^g	.001	12.3 (12.0–12.5)	0.6 (0.3–0.8) ^g	< .001
Liver and intrahepatic bile duct	11	13.4 (13.3–13.4)	0.4 (−0.5, 1.3)	.42	11.2 (11.1–11.3)	1.3 (0.5–2.1) ^g	.003	18.2 (17.9–18.5)	−2.3 (−4.7, 0.2)	.07	19.6 (19.1–20.0)	−2.1 (−3.1, −1.1) ^g	.001	27.9 (26.1–29.8)	4.6 (3.3–6.0) ^g	< .001	20.1 (19.8–20.4)	0.4 (−0.3, 1.1)	.25
Myeloma	12	9.2 (9.1–9.2)	0.0 (−0.8, 0.9)	.97	8.3 (8.3–8.4)	0.0 (−1.2, 1.1)	.96	18.0 (17.7–18.3)	0.1 (−1.8, 2.0)	.92	5.3 (5.0–5.5)	−1.2 (−3.4, 1.1)	.28	10.8 (9.6–12.2)	2.4 (0.9–4.0) ^g	.004	8.4 (8.2–8.6)	1.2 (0.7–1.7) ^g	< .001
Stomach	13	8.8 (8.8–8.9)	−1.8 (−2.5, −1.1) ^g	< .001	7.5 (7.4–7.6)	−1.6 (−2.0, −1.2) ^g	< .001	13.5 (13.3–13.8)	−1.9 (−2.1, −1.7 ^g )	< .001	12.8 (12.5–13.2)	−2.9 (−3.2, −2.5) ^g	< .001	13.4 (12.0–14.8)	−2.0 (−2.9, −1.0) ^g	.001	11.9 (11.6–12.1)	−1.9 (−2.2, −1.7) ^g	< .001
Esophagus	14	7.9 (7.8–8.0)	−0.2 (−0.7, 0.2)	.26	8.8 (8.7–8.9)	0.3 (−0.2, 0.9)	.22	6.1 (5.9–6.2)	−4.6 (−4.9, −4.4) ^g	< .001	3.6 (3.4–3.8)	−1.0 (−1.8, −0.2) ^g	.02	9.5 (8.5–10.7)	0.6 (−1.0, 2.2)	.42	4.9 (4.7–5.1)	−1.5 (−1.9, −1.1) ^g	< .001
Brain and other nervous system	15	7.8 (7.7–7.8)	−0.3 (−0.4, −0.2) ^g	< .001	8.8 (8.8–8.9)	0.0 (−0.1, 0.1)	.51	4.9 (4.7–5.1)	0.1 (−0.3, 0.5)	.68	4.6 (4.4–4.8)	0.3 (−0.3, 0.9)	.29	6.8 (5.9–7.8)	1.2 (−0.4, 2.8)	.13	5.8 (5.6–5.9)	−0.6 (−0.9, −0.4) ^g	< .001
Thyroid	16	7.4 (7.4–7.5)	−1.7 (−3.0, −0.4) ^g	.02	8.2 (8.2–8.3)	−1.7 (−3.0, −0.3) ^g	.02	3.9 (3.8–4.0)	−5.8 (−9.7, −1.8) ^g	.009	7.6 (7.4–7.9)	−0.5 (−2.8, 1.9)	.66	6.1 (5.3–7.0)	4.7 (2.8–6.7) ^g	< .001	6.3 (6.2–6.5)	−0.3 (−3.7, 3.2)	.86
Testis	17	5.8 (5.8–5.9)	0.5 (0.4–0.7) ^g	< .001	7.1 (7.0–7.2)	0.5 (0.3–0.7) ^g	< .001	1.6 (1.5–1.7)	1.1 (0.4–1.7) ^g	.003	2.1 (2.0–2.3)	2.2 (1.3–3.1) ^g	< .001	7.5 (6.6–8.4)	2.4 (0.9–4.0) ^g	.004	5.3 (5.2–5.5)	3.7 (2.9–4.5) ^g	< .001
Larynx	18	5.5 (5.4–5.5)	−2.4 (−2.5, −2.3) ^g	< .001	5.6 (5.5–5.6)	−2.5 (−2.9, −2.0) ^g	< .001	7.9 (7.8–8.2)	−3.2 (−3.4, −2.9) ^g	< .001	2.0 (1.9–2.2)	−2.4 (−3.5, −1.3) ^g	< .001	6.7 (5.8–7.7)	−0.6 (−2.0, 0.8)	.39	4.5 (4.3–4.6)	−3.2 (−3.6, −2.9) ^g	< .001
Females
Breast	1	128.5 (128.2–128.7)	0.5 (0.4–0.6) ^g	< .001	134.7 (134.4–135.0)	0.6 (0.4–0.7) ^g	< .001	129.7 (129.0–130.4)	−0.3 (−1.3, 0.7)	.59	102.1 (101.2–103.0)	1.9 (1.6, 2.1) ^g	< .001	119.1 (115.6–122.8)	−1.8 (−5.3, 1.9)	.31	98.7 (98.1–99.3)	1.1 (0.7–1.5) ^g	< .001
Lung and bronchus	2	51.0 (50.9–51.1)	−1.1 (−1.2, −0.9) ^g	< .001	56.8 (56.6–56.9)	−0.8 (−1.0, −0.7) ^g	< .001	47.8 (47.4–48.3)	−1.6 (−1.9, −1.3) ^g	< .001	28.6 (28.1–29.1)	0.1 (−0.1, 0.3)	.33	61.5 (59.0–64.2)	0.3 (−0.1, 0.8)	.14	23.1 (22.8–23.4)	−0.7 (−0.9, −0.5) ^g	< .001
Colon and rectum	3	33.9 (33.7–34.0)	−1.2 (−1.9, −0.5) ^g	.001	33.9 (33.8–34.0)	−1.1 (−1.6, −0.7) ^g	< .001	39.1 (38.7–39.5)	−1.9 (−2.5, −1.3) ^g	< .001	26.0 (25.6–26.5)	−2.3 (−2.5, −2.0) ^g	< .001	48.4 (46.1–50.7)	−0.2 (−0.7, 0.3)	.41	30.0 (29.7–30.3)	0.0 (−0.7, 0.8)	.89
Corpus and uterus, NOS	4	27.7 (27.6–27.8)	0.8 (−0.1, 1.7)	.07	28.1 (28.0–28.3)	0.4 (−0.4, 1.1)	.32	28.5 (28.1–28.8)	2.4 (2.2–2.5) ^g	< .001	21.0 (20.6–21.4)	2.5 (2.2–2.7) ^g	< .001	29.8 (28.1–31.6)	2.1 (1.5–2.8) ^g	< .001	25.2 (25.0–25.5)	2.2 (1.9–2.4) ^g	< .001
Thyroid	5	21.2 (21.1–21.3)	−2.9 (−3.9, −1.8) ^g	< .001	22.3 (22.2–22.4)	−3.1 (−4.4, −1.8) ^g	< .001	13.5 (13.2–13.7)	−5.3 (−7.8, −2.7) ^g	.001	22.6 (22.2–23.1)	−1.1 (−2.4, 0.2)	.08	21.7 (20.2–23.2)	5.5 (4.5–6.5) ^g	< .001	23.1 (22.8–23.4)	−0.6 (−2.5, 1.4)	.55
Melanoma of the skin	6	18.2 (18.2–18.3)	1.8 (1.6–2.0) ^g	< .001	25.0 (24.9–25.1)	2.4 (2.1–2.7) ^g	< .001	0.9 (0.9–1.0)	−0.9 (−1.6, −0.1) ^g	.03	1.3 (1.2–1.4)	−0.4 (−1.4, 0.6)	.42	9.4 (8.3–10.5)	3.3 (2.1–4.5) ^g	< .001	4.6 (4.4, 4.7)	0.7 (0.1, 1.3) ^g	.04
Non‐Hodgkin lymphoma	7	16.3 (16.2–16.4)	−0.1 (−0.2, 0.0) ^g	.03	17.0 (16.9–17.1)	−0.2 (−0.3, 0.0) ^g	.01	12.7 (12.5–12.9)	0.5 (0.2–0.7) ^g	< .001	11.4 (11.1–11.7)	0.2 (−0.2, 0.7)	.28	16.4 (15.0–17.8)	−0.1 (−0.8, 0.7)	.83	15.7 (15.4, 15.9)	0.3 (0.1–0.6) ^g	.005
Kidney and renal pelvis	8	12.0 (12.0–12.1)	1.2 (0.8–1.7) ^g	< .001	12.1 (12.0–12.2)	1.3 (0.7–1.9) ^g	.001	13.8 (13.6–14.0)	0.5 (0.0–1.0) ^g	.05	5.6 (5.4–5.9)	1.4 (0.7–2.1) ^g	.001	23.4 (21.8–25.0)	2.3 (1.4–3.2) ^g	< .001	12.3 (12.1, 12.5)	1.6 (1.4–1.9) ^g	< .001
Leukemia	9	11.9 (11.8–11.9)	0.1 (−0.3, 0.6) ^g	.54	12.5 (12.4–12.6)	0.2 (−0.4, 0.8)	.41	9.7 (9.6–9.9)	0.1 (−0.8, 1.0)	.86	7.0 (6.7–7.2)	1.2 (0.8–1.6) ^g	< .001	11.0 (9.9–12.1)	1.6 (0.4–2.9) ^g	.01	10.1 (9.9, 10.3)	1.0 (0.7–1.3) ^g	< .001
Pancreas	10	11.6 (11.5–11.7)	1.0 (1.0–1.1) ^g	< .001	11.4 (11.3–11.5)	1.1 (1.0–1.2) ^g	< .001	15.2 (15.0–15.5)	0.7 (0.5–1.0) ^g	< .001	9.0 (8.7–9.2)	0.8 (0.5–1.1) ^g	< .001	12.6 (11.4–13.8)	1.0 (0.0–2.1) ^g	.05	10.5 (10.3–0.7)	0.9 (0.6–1.1) ^g	< .001
Ovary	11	10.9 (10.9–11.0)	−2.5 (−3.5, −1.5) ^g	< .001	11.3 (11.2–11.4)	−2.9 (−4.2, −1.7) ^g	< .001	9.0 (8.8–9.2)	−1.0 (−1.3, −0.7) ^g	< .001	9.4 (9.2–9.7)	−0.2 (−0.6, 0.1)	.22	13.1 (11.9–14.3)	−0.3 (−1.5, 1.0)	.68	10.0 (9.9–10.2)	−1.2 (−1.5, −1.0) ^g	< .001
Urinary bladder	12	8.6 (8.5–8.6)	−0.9 (−1.1, −0.8) ^g	< .001	9.6 (9.6–9.7)	−0.7 (−0.9, −0.6) ^g	< .001	6.7 (6.5–6.8)	−0.6 (−0.8, −0.3) ^g	< .001	3.7 (3.5–3.9)	−0.7 (−1.4, 0.0) ^g	.04	6.5 (5.6–7.4)	1.7 (0.2–3.1) ^g	.03	5.0 (4.8–5.1)	−1.1 (−1.5, −0.6) ^g	< .001
Cervix	13	7.9 (7.8–7.9)	0.1 (−2.5, 2.8)	.92	7.4 (7.3–7.5)	0.1 (−2.8, 3.1)	.95	9.0 (8.8–9.2)	−1.7 (−2.2, −1.2) ^g	< .001	6.2 (6.0–6.5)	−1.5 (−2.1, −0.9) ^g	< .001	11.5 (10.4–12.7)	0.5 (−0.4, 1.4)	.27	9.9 (9.8–10.1)	0.3 (−0.9, 1.5)	.61
Oral cavity and pharynx	14	6.6 (6.5–6.6)	0.5 (0.4–0.6) ^g	< .001	7.2 (7.1–7.3)	0.9 (0.7–1.0) ^g	< .001	5.2 (5.0–5.3)	−0.7 (−1.0, −0.5) ^g	< .001	5.3 (5.1–5.5)	0.1 (−0.6, 0.7)	.82	7.0 (6.2–7.9)	0.5 (−1.1, 2.1)	.52	4.5 (4.3–4.6)	0.5 (0.0–1.0)	.06
Myeloma	15	6.0 (6.0–6.1)	1.4 (1.0–1.7) ^g	< .001	5.1 (5.0–5.1)	1.0 (0.5–1.5) ^g	.002	13.3 (13.1–13.5)	2.1 (1.8–2.4) ^g	< .001	3.3 (3.1–3.5)	0.9 (0.3–1.6) ^g	.006	7.8 (6.9–8.8)	1.4 (−0.1, 2.9)	.07	6.1 (6.0–6.3)	2.2 (1.5–2.8) ^g	< .001
Brain and other nervous system	16	5.6 (5.5–5.6)	−0.5 (−0.7, −0.3) ^g	< .001	6.4 (6.3–6.4)	−0.3 (−0.5, −0.1) ^g	.008	3.6 (3.5–3.7)	−0.4 (−0.8, 0.0)	.07	3.3 (3.2–3.5)	0.3 (−0.3, 0.8)	.32	4.7 (4.1–5.5)	0.7 (−1.3, 2.8)	.45	4.6 (4.5–4.7)	−0.3 (−0.7, 0.0)	.06
Liver and intrahepatic bile duct	17	4.8 (4.7–4.8)	1.6 (0.3–3.0) ^g	.02	4.0 (4.0–4.1)	3.8 (3.5–4.1) ^g	< .001	5.6 (5.5–5.8)	0.7 (−1.9, 3.3)	.59	7.3 (7.0–7.5)	−4.6 (−7.7, −1.4) ^g	.009	11.8 (10.7–12.9)	3.3 (2.0–4.6) ^g	< .001	7.9 (7.7–8.0)	2.3 (2.0–2.6) ^g	< .001
Stomach	18	4.7 (4.7–4.8)	0.1 (−0.2, 0.4)	.36	3.5 (3.5–3.6)	0.0 (−0.5, 0.4)	.83	7.6 (7.4–7.7)	−1.2 (−1.4, −0.9) ^g	< .001	7.5 (7.3–7.8)	−2.6 (−3.1, −2.2) ^g	< .001	7.9 (7.0–8.9)	−0.3 (−1.6, 1.1)	.68	7.7 (7.5–7.8)	−1.0 (−1.4, −0.7) ^g	< .001
Children
Leukemia		5.3 (5.2–5.4)	0.7 (0.4–1.0) ^g	< .001	5.2 (5.1–5.4)	0.5 (0.3–0.8) ^g	.001	3.3 (3.1–3.5)	1.2 (0.6–1.7) ^g	< .001	5.8 (5.4–6.1)	1.1 (0.4–1.8) ^g	.006	6.6 (5.6–7.9)	1.0 (−1.0, 2.9)	.31	6.4 (6.2–6.6)	0.8 (0.3–1.2) ^g	.002
Brain and other nervous system		3.8 (3.7–3.9)	0.7 (0.4–1.0) ^g	< .001	4.3 (4.2–4.4)	0.8 (0.5–1.2) ^g	< .001	3.0 (2.8–3.2)	1.3 (0.7–2.0) ^g	< .001	3.1 (2.8–3.3)	1.4 (0.4–2.4) ^g	.01	3.6 (2.8–4.5)	— ^h		3.1 (2.9–3.2)	0.1 (−0.3, 0.5)	.62
Lymphoma		1.7 (1.6–1.7)	0.9 (0.6–1.3) ^g	< .001	1.7 (1.7–1.8)	1.0 (0.4–1.5) ^g	.001	1.6 (1.5–1.8)	1.4 (0.6–2.1) ^g	.001	1.6 (1.4–1.8)	1.0 (−0.2, 2.3)	.09	1.5 (1.0–2.1)	— ^h		1.5 (1.4–1.6)	0.2 (−0.3, 0.7)	.35
AYAs
Thyroid		12.0 (11.9–12.0)	−2.0 (−3.6, −0.3) ^g	.02	13.6 (13.4–13.7)	−2.7 (−4.5, −0.7) ^g	.007	5.5 (5.3–5.6)	−6.0 (−9.7, −2.2) ^g	.005	12.7 (12.3–13.0)	0.1 (−1.7, 1.9)	.92	13.2 (11.8–14.6)	5.2 (4.1–6.3) ^g	< .001	10.8 (10.6–11.0)	0.7 (−2.7, 4.3)	.65
Female breast		22.8 (22.6–23.0)	1.0 (0.6–1.4) ^g	< .001	23.5 (23.2–23.7)	0.6 (0.5–0.8) ^g	< .001	27.0 (26.5–27.6)	0.3 (0.1–0.6) ^g	.02	20.4 (19.8–21.1)	0.9 (0.5–1.4) ^g	< .001	21.7 (19.2–24.4)	1.3 (−0.2, 2.8)	.10	18.3 (17.9–18.7)	1.8 (0.9–2.8) ^g	.001
Lymphoma		7.7 (7.6–7.8)	−0.4 (−0.5, −0.3) ^g	< .001	8.2 (8.1–8.3)	−0.4 (−0.6, −0.3) ^g	< .001	8.3 (8.1–8.5)	−0.8 (−1.3, −0.4) ^g	.001	5.6 (5.3–5.8)	2.0 (1.6–2.5) ^g	< .001	6.0 (5.2–7.0)	1.4 (−0.6, 3.4)	.17	6.2 (6.1–6.4)	0.8 (0.0–1.7) ^g	.05
Melanoma of the skin		6.7 (6.6–6.7)	−0.8 (−1.2, −0.5) ^g	< .001	10.6 (10.4–10.7)	−0.5 (−1.0, 0.0) ^g	.05	0.2 (0.2–0.3)	−1.8 (−3.4, −0.1) ^g	.04	0.5 (0.4–0.6)	−1.7 (−3.2, −0.3) ^g	.02	4.1 (3.3–5.0)	0.8 (−0.8, 2.4)	.29	1.2 (1.2–1.3)	−1.6 (−2.2, −0.9) ^g	< .001
Testis		11.1 (11.0–11.3)	0.8 (0.6–0.9) ^g	< .001	13.5 (13.3–13.7)	0.5 (0.3–0.7) ^g	< .001	2.6 (2.5–2.8)	0.8 (−0.2, 1.7)	.10	4.2 (3.9–4.5)	2.8 (1.7–3.8) ^g	< .001	14.6 (12.7–16.7)	1.3 (−0.1, 2.7)	.07	11.6 (11.3–11.8)	3.0 (2.7–3.4) ^g	< .001
Colon and rectum		5.1 (5.0–5.2)	5.0 (3.7–6.4) ^g	< .001	5.6 (5.5–5.7)	3.2 (0.8–5.7) ^g	.009	4.9 (4.8–5.1)	3.1 (2.1–4.1) ^g	< .001	3.4 (3.2–3.6)	1.2 (0.3–2.1) ^g	.01	7.6 (6.6–8.8)	3.4 (1.2–5.6) ^g	.005	4.1 (4.0–4.3)	8.4 (6.1–10.8) ^g	< .001

Abbreviations: AAPC, average annual percent change; AI/AN, American Indian/Alaska Native; APC, annual percent change; API, Asian/Pacific Islander; AYA, adolescents and young adults; NOS, not otherwise specified; PRCDA, Indian Health Service Purchased/Referred Care Delivery Area.

^{^a}

Rates are per 100,000 persons and were age standardized to the 2000 US standard population (19 age groups; US Bureau of the Census. Current Population Report P25‐1130. US Government Printing Office; 2000).

^{^b}

The AAPC is the average APC and is a weighted average of the APCs over the fixed interval 2014–2018 using the underlying joinpoint model for the period of 2001–2018. Joinpoint models with up to three joinpoints are based on rates per 100,000 persons and are age standardized to the 2000 US standard population (19 age groups; US Bureau of the Census, Current Population Report P25‐1130; National Cancer Institute; Joinpoint Regression Program, version 4.9.0.0; Surveillance Research Program, National Cancer Institute; 2021).

^{^c}

Cancers are sorted in descending order according to sex‐specific rates for all racial/ethnic groups. More than 15 cancers may appear under males and females to include the top 15 cancers in every racial/ethnic group.

^{^d}

White, Black, API, and AI/AN (PRCDA 2017 counties) include non‐Hispanic; the racial/ethnic categories are mutually exclusive.

^{^e}

Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program areas reported by the North American Association of Central Cancer Registries as meeting high‐quality incidence data standards for the specified time periods. Registries included in the joinpoint models (2001–2018) for all racial/ethnic groups, White, Black, AI/AN, API, Hispanic, and non‐Hispanic (46 states): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Texas, Utah, Vermont, Washington, West Virginia, Wisconsin, and Wyoming. Registries included in the incidence rates (2014–2018) for all racial/ethnic groups, White, Black, AI/AN, API, Hispanic, and non‐Hispanic (49 states, the District of Columbia, and one territory): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.

^{^f}

For all sites, myelodysplastic syndromes are included for the rate and APC calculations; they are excluded from cancer‐specific analysis. Ovary excludes borderline tumors.

^{^g}

The AAPC is statistically significantly different from zero (two‐sided p < .05).

^{^h}

The statistic could not be calculated. The AAPC is based on <10 cases for at least 1 year within the time interval.